HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)

Primary hyperaldosteronism confers a higher risk of cardiovascular complications compared to essential hypertension. Preliminary data is controversial in regards of excessive maternal fetal and neonatal excessive risks in pregnancy.This study aims at establishing the prevalence of PHA in an population with a recent episode of hypertensive disorder of pregnancy (HDP). The goal is to determine if a universal screening for PHA after a HDP is worthed. The investigators also wish to evaluate the complication rate in pregnant women with PHA compared to women without PHA.This is a prospective cohort study where all eligible women will be screened for PHA after a HDP episode in the last pregnancy. We will then compare PHA women to non PHA women according to pregnancy complications.

Inclusion Criteria:Between 4 and 24 weeks post-partum women who had a hypertensive disorder during their latest pregnancy.Exclusion Criteria:Ongoing pregnancyDiagnosed pheochromocytomaDiagnosed Cushing syndromeDiagnosed secondary hyperaldosteronism